Drugs / Ciforadenant
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04280328 | Feb 2020 → Sep 2021 | plasma cell myeloma | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03454451 | Apr 2018 → Dec 2022 | castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02655822 | Jan 2016 → Jun 2021 | castration-resistant prostate carcinoma, renal cell carcinoma | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02764892 | Aug → Nov 2012 | Parkinson disease | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01634568 | Aug 2011 → Feb 2012 | Parkinson disease | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05501054 | Feb 2023 → Nov 2026 expected | renal cell carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT02253745 | Jul 2013 → Mar 2014 | attention deficit-hyperactivity disorder | Vernalis (R&D) Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03237988 Comparator | Jul → Sep 2017 | — | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ciforadenant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05501054 ↗ |
| Known as | CPI-444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03237988 ↗ |
| Known as | V81444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01634568 ↗ |
| Action | Inhibit | “Ciforadenant blocks adenosine from binding to the A2A receptor.” NCT02655822 ↗1“Adenosine A2a receptor antagonist” CHEMBL4297184 ↗ |
| Modality | Small molecule | “ciforadenant, an oral small molecule targeting the adenosine-A2A receptor” NCT02655822 ↗ |
| Route | Oral | “single oral dose of V81444” NCT01634568 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL4297184 ↗ |